Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)
Robert HI Andtbacka, Frances A Collichio, Thomas Amatruda, Neil Senzer, Jason Chesney, Keith Delman, Lynn Spitler, Igor Puzanov, Sanjiv Agarwala, Mohammed Milhem, Kevin Harrington, Mark Middleton, Ai Li, Mark Shilkrut, Robert Coffin, Howard Kaufman
Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P263; DOI: 10.1186/2051-1426-2-S3-P263
